HER2 testing: current status and future directions.
Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.
Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL 32224, USA. Electronic address: perez.edith@mayo.edu.
Edith A
EA
Perez
Javier
J
Cortés
Ana Maria
AM
Gonzalez-Angulo
John M S
JM
Bartlett
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D017410:Practice Guidelines as Topic; D060888:Real-Time Polymerase Chain Reaction; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D015203:Reproducibility of Results; D012955:Societies, Medical; D014481:United States; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines; Human epidermal growth factor receptor 2 (HER2) testing; Immunohistochemistry; In situ hybridization; Variability